News >

Chari Highlights Emerging Options in Heavily Pretreated Myeloma

Brandon Scalea
Published: Friday, Jan 25, 2019

Ajai Chari, MD

Ajai Chari, MD

Several treatment options are emerging for patients with heavily pretreated multiple myeloma, explained Ajai Chari, MD.

In November 2018, the FDA granted a priority review designation to a new drug application (NDA) for selinexor for the treatment of patients with penta-refractory multiple myeloma. The NDA was submitted based on positive data from the phase IIb STORM trial, which showed that the combination of selinexor and dexamethasone demonstrated an overall response rate (ORR) of 26.2% and a duration of response of 4.4 months.1

In the heavily pretreated patients who were refractory to proteasome inhibitors, immunomodulatory agents (IMiDs), at least one alkylating agent, and glucocorticoids, a clinical benefit rate of 39.3% was observed with the combination. Median overall survival was 8.6 months.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication